Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5010, Tv
2. Acetate, Glatiramer
3. Copaxone
4. Glatiramer
5. Tv 5010
6. Tv-5010
7. Tv5010
1. 147245-92-9
2. Acetic Acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic Acid;(2s)-2-aminopentanedioic Acid;(2s)-2-aminopropanoic Acid;(2s)-2,6-diaminohexanoic Acid
3. Glatirameracetat
4. Dtxsid30163637
5. Am84438
6. Ac-28732
7. L-alanine Compound With L-glutamic Acid And L-lysine And L-tyrosine And Acetic Acid (1:1:1:1:1)
8. Q418274
Molecular Weight | 623.7 g/mol |
---|---|
Molecular Formula | C25H45N5O13 |
Hydrogen Bond Donor Count | 12 |
Hydrogen Bond Acceptor Count | 18 |
Rotatable Bond Count | 13 |
Exact Mass | 623.30138651 g/mol |
Monoisotopic Mass | 623.30138651 g/mol |
Topological Polar Surface Area | 374 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 519 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 5 |
1 of 2 | |
---|---|
Drug Name | Copaxone |
PubMed Health | Glatiramer (Injection) |
Drug Classes | Central Nervous System Agent, Immune Suppressant, Musculoskeletal Agent |
Drug Label | Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.... |
Active Ingredient | Glatiramer acetate |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 20mg/ml; 40mg/ml |
Market Status | Prescription |
Company | Teva Pharms Usa |
2 of 2 | |
---|---|
Drug Name | Copaxone |
PubMed Health | Glatiramer (Injection) |
Drug Classes | Central Nervous System Agent, Immune Suppressant, Musculoskeletal Agent |
Drug Label | Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.... |
Active Ingredient | Glatiramer acetate |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 20mg/ml; 40mg/ml |
Market Status | Prescription |
Company | Teva Pharms Usa |
Antirheumatic Agents
Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
L03AX13
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L03 - Immunostimulants
L03A - Immunostimulants
L03AX - Other immunostimulants
L03AX13 - Glatiramer acetate
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-05-05
Pay. Date : 2013-12-31
DMF Number : 25855
Submission : 2012-03-24
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-945
Start Marketing Date : 2012-03-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7609
Submission : 1988-08-02
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33092
Submission : 2018-09-12
Status : Active
Type : II
Date of Issue : 2022-08-04
Valid Till : 2025-03-04
Written Confirmation Number : WC-0427A3-4
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-02-08
Pay. Date : 2020-12-24
DMF Number : 35493
Submission : 2020-12-25
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-03-07
Pay. Date : 2018-02-09
DMF Number : 28989
Submission : 2014-12-25
Status : Active
Type : II
NDC Package Code : 14403-0008
Start Marketing Date : 2025-01-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-06-05
Pay. Date : 2013-11-22
DMF Number : 27723
Submission : 2013-12-12
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-01-05
Pay. Date : 2014-06-09
DMF Number : 26489
Submission : 2012-09-27
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
17
PharmaCompass offers a list of Glatiramer Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Glatiramer Acetate manufacturer or Glatiramer Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Glatiramer Acetate manufacturer or Glatiramer Acetate supplier.
PharmaCompass also assists you with knowing the Glatiramer Acetate API Price utilized in the formulation of products. Glatiramer Acetate API Price is not always fixed or binding as the Glatiramer Acetate Price is obtained through a variety of data sources. The Glatiramer Acetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt), including repackagers and relabelers. The FDA regulates L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) supplier is an individual or a company that provides L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) active pharmaceutical ingredient (API) or L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) finished formulations upon request. The L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers may include L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) API manufacturers, exporters, distributors and traders.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) DMF (Drug Master File) is a document detailing the whole manufacturing process of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) active pharmaceutical ingredient (API) in detail. Different forms of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) DMFs exist exist since differing nations have different regulations, such as L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) DMF submitted to regulatory agencies in the US is known as a USDMF. L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) USDMF includes data on L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers with USDMF on PharmaCompass.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) written confirmation (L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) WC) is an official document issued by a regulatory agency to a L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) manufacturer, verifying that the manufacturing facility of a L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) APIs or L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) finished pharmaceutical products to another nation, regulatory agencies frequently require a L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) WC (written confirmation) as part of the regulatory process.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) suppliers with NDC on PharmaCompass.
L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) GMP manufacturer or L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) GMP API supplier for your needs.
A L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) CoA (Certificate of Analysis) is a formal document that attests to L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)'s compliance with L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) specifications and serves as a tool for batch-level quality control.
L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) CoA mostly includes findings from lab analyses of a specific batch. For each L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) may be tested according to a variety of international standards, such as European Pharmacopoeia (L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) EP), L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) USP).